Abstract Exportin 1 (XPO1), also known as chromosome region maintenance protein 1,
plays a crucial role in maintaining cellular homeostasis via the regulated export of a range of …

Cellular homeostasis requires the proper nuclear-cytoplasmic partitioning of large
molecules, which is often deregulated in cancer. XPO1 is an export receptor responsible for …

Background Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is an aggressive
cancer with a median overall survival of less than 6 months. We aimed to assess the …

Richter syndrome (RS) is the development of an aggressive lymphoma in patients with
chronic lymphocytic leukemia (CLL). Two pathologic variants of RS are recognized: namely …

Purpose Selinexor, a first-in-class, oral, selective exportin 1 (XPO1) inhibitor, induces
apoptosis in cancer cells through nuclear retention of tumor suppressor proteins and the …

Selinexor (XPOVIO™) is a first-in-class, oral, small molecule Exportin-1 (XPO1) inhibitor that
is being developed by Karyopharm Therapeutics for the treatment of cancer. Selinexor (in …

The incidence of lymphoma has gradually increased over previous decades, and it ranks
among the ten most prevalent cancers worldwide. With the development of targeted …

Newer, more effective and non-cytotoxic therapies are an unmet need for patients with
diffuse large B-cell lymphoma (DLBCL) and other B-cell malignancies. Recently approved …

Novel therapies are needed for patients with relapsed or refractory multiple myeloma (MM).
We conducted a multicenter, phase 1 study in advanced hematological malignancies to …

Therapies targeted at inhibiting nucleo-cytoplasmic transport have found broad applications
in the field of oncology. Chromosome region maintenance 1 (CRM1), better known as …